GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » Sloan Ratio %

Baxter International (Baxter International) Sloan Ratio % : -7.12% (As of Mar. 2024)


View and export this data going back to 1961. Start your Free Trial

What is Baxter International Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Baxter International's Sloan Ratio for the quarter that ended in Mar. 2024 was -7.12%.

As of Mar. 2024, Baxter International has a Sloan Ratio of -7.12%, indicating the company is in the safe zone and there is no funny business with accruals.


Baxter International Sloan Ratio % Historical Data

The historical data trend for Baxter International's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Sloan Ratio % Chart

Baxter International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 2.06 30.61 -9.59 -8.07

Baxter International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.12 -13.01 -7.27 -8.07 -7.12

Competitive Comparison of Baxter International's Sloan Ratio %

For the Medical Instruments & Supplies subindustry, Baxter International's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Baxter International's Sloan Ratio % falls into.



Baxter International Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Baxter International's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(2656-1726
-3213)/28276
=-8.07%

Baxter International's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(2649-1410
-3217)/27788
=-7.12%

Baxter International's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -141 (Jun. 2023 ) + 2508 (Sep. 2023 ) + 245 (Dec. 2023 ) + 37 (Mar. 2024 ) = $2,649 Mil.
Baxter International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 351 (Jun. 2023 ) + 365 (Sep. 2023 ) + 531 (Dec. 2023 ) + 163 (Mar. 2024 ) = $1,410 Mil.
Baxter International's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -173 (Jun. 2023 ) + 3786 (Sep. 2023 ) + -230 (Dec. 2023 ) + -166 (Mar. 2024 ) = $3,217 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxter International  (NYSE:BAX) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Baxter International has a Sloan Ratio of -7.12%, indicating the company is in the safe zone and there is no funny business with accruals.


Baxter International Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Baxter International's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxter International (Baxter International) Business Description

Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
Executives
Joel T. Grade officer: EVP, Chief Financial Officer SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth officer: EVP, Group Pres, Kidney Care 1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul officer: EVP, Group Pres, Healthcare ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig officer: EVP, Group President, Pharm ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight officer: EVP, Group Pres, Medical ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler officer: SVP, Chief Quality Officer ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jeanne K Mason officer: CVP, Human Resources ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn officer: SVP, President, APAC ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver director
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Cathy R Smith director TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403